| Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights |
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2025, and reviewed recent business highlights. “Silence delivered another strong quarter focused on clinical and operational execution,” said Craig Tooman, President and Chief Executive Officer at Silence. “We remain focused on advancing enr. |
businesswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| Silence Therapeutics Welcomes Tim McInerney to Board of Directors |
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting (“AGM”) in June 2025. “We are thrilled to welcome Tim to the Silence Board,” said Iain Ross, Chairman of the Sil. |
businesswire.com |
2025-05-06 11:45:00 |
Czytaj oryginał (ang.) |
| Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference |
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the Leerink Partners Global Healthcare Conference on Wednesday, March 12th at 1:00 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be. |
businesswire.com |
2025-03-05 10:00:00 |
Czytaj oryginał (ang.) |
| Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know |
Silence Therapeutics (SLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-03-04 15:05:32 |
Czytaj oryginał (ang.) |
| Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript |
Silence Therapeutics plc (NASDAQ:SLN ) Q4 2024 Earnings Call February 27, 2025 8:00 AM ET Company Participants Gem Hopkins - Vice President, Investor Relations and Corporate Communications Craig Tooman - President and Chief Executive Officer Rhonda Hellums - Chief Financial Officer Steven Romano - Chief R&D Officer Conference Call Participants Mike Ulz - Morgan Stanley Kostas Biliouris - BMO Capital Markets Richard Law - Goldman Sachs Keay Nakae - Chardan Myles Minter - William Blair Gem Hopkins Good morning and good afternoon, everyone. Thank you for joining us today. |
seekingalpha.com |
2025-02-28 13:59:32 |
Czytaj oryginał (ang.) |
| Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update |
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update. “2024 was marked by strong clinical execution and pipeline advancement, highlighting the broad potential of our mRNAi GOLD™ platform to silence disease causing genes,” said Craig Tooman, President and CEO. |
businesswire.com |
2025-02-27 09:30:00 |
Czytaj oryginał (ang.) |
| Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting |
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced additional results from the Phase 1 open label portion of the SANRECO study of divesiran, a siRNA targeting TMPRSS6, in patients with polycythemia vera (PV) were presented at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, California. “Additional divesiran data pres. |
businesswire.com |
2024-12-09 09:30:00 |
Czytaj oryginał (ang.) |
| Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference |
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4th at 10:00 a.m. ET. The live webcast can be accessed via the Investors section of the Silence website at www.sile. |
businesswire.com |
2024-11-26 10:00:00 |
Czytaj oryginał (ang.) |
| SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels |
Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile. |
zacks.com |
2024-11-20 14:06:17 |
Czytaj oryginał (ang.) |
| Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst |
On Monday, Silence Therapeutics plc SLN presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L). |
benzinga.com |
2024-11-19 17:34:42 |
Czytaj oryginał (ang.) |
| Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting |
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L). These data were presen. |
businesswire.com |
2024-11-18 16:30:00 |
Czytaj oryginał (ang.) |
| Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy' |
Silence Therapeutics focuses on RNA interference therapies, with its lead candidates targeting cardiovascular and hematological diseases via the mRNAi GOLD platform. Zerlasiran, the company's main value driver, aims to reduce lipoprotein(a) levels, potentially lowering cardiovascular risks in 20-25% of the global population. Divesiran shows promise in early trials for Polycythemia Vera. Early clinical trial data suggests it can effectively regulate red blood cell production. |
seekingalpha.com |
2024-09-08 13:13:46 |
Czytaj oryginał (ang.) |
| Silence: Additional siRNA Drug Data Leads To Next Stages Of Development |
Silence Therapeutics plc's positive results achieved from phase 1 SANRECO study using divesiran for the treatment of patients with polycythemia vera. The global polycythemia vera treatment market size is predicted to reach $45 billion by the end of 2036. Full detailed results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, are to be presented at an upcoming medical conference before the end of 2024. |
seekingalpha.com |
2024-09-05 18:18:59 |
Czytaj oryginał (ang.) |
| Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences |
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that management will present company overviews at the following conferences: Morgan Stanley Global Healthcare Conference on Thursday, September 5, 2024 at 5:35pm ET HC Wainwright Global Investment Conference on Tuesday, September 10, 2. |
businesswire.com |
2024-08-27 12:00:00 |
Czytaj oryginał (ang.) |
| The 3 Best Gene Editing Stocks to Buy in August 2024 |
Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030. |
investorplace.com |
2024-08-07 13:00:00 |
Czytaj oryginał (ang.) |
| Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks |
Wall Street likes to peer into the fog of the future and guess where a stock is headed. While these stock price predictions are based on educated estimates, often based on information and models unavailable to regular investors, they are nonetheless guesses. |
investorplace.com |
2024-07-25 10:08:00 |
Czytaj oryginał (ang.) |
| Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last? |
Silence Therapeutics (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-07-12 15:11:30 |
Czytaj oryginał (ang.) |
| Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration |
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples' lives by silencing diseases through precision engineered medicines, today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (“Hansoh”) following the achievement of a second undisclosed milestone related to the first target under the collaboration. “This represe. |
businesswire.com |
2024-06-24 12:30:00 |
Czytaj oryginał (ang.) |
| Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results |
Silence Therapeutics plc results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, expected end of June 2024. The 7 major polycythemia vera markets are expected to reach $68.5 billion by 2034. Positive results achieved in the phase 2 ALPACAR-360 study using zerlasiran for patients with elevated levels of Lp[a] at high risk of ASCVD. |
seekingalpha.com |
2024-06-21 18:31:06 |
Czytaj oryginał (ang.) |
| Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a) |
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced positive topline 48-week data from the ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or Lp(a), levels at or over 125 nmol/L at high risk of atherosclerotic cardiovascular disease (ASCVD). |
businesswire.com |
2024-06-20 11:30:00 |
Czytaj oryginał (ang.) |
| Silence Therapeutics to Present at Jefferies Global Healthcare Conference |
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the Company will present at the Jefferies Global Healthcare Conference on Thursday, June 6th at 2:30 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archive. |
businesswire.com |
2024-05-30 12:30:00 |
Czytaj oryginał (ang.) |
| Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress |
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today reported its financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights. “Silence's first quarter performance reflects another period of solid execution with the continued advancement of both our wholly. |
businesswire.com |
2024-05-16 12:30:00 |
Czytaj oryginał (ang.) |
| Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference |
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20th at 2:30 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at. |
businesswire.com |
2024-04-30 12:30:00 |
Czytaj oryginał (ang.) |
| Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors |
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence's Board of Directors (the “Board”) since 2015, informed the Company that he will retire from the Board, effective May 1, 2024. Iain Ross, Silence's Chairman of the. |
businesswire.com |
2024-04-29 12:30:00 |
Czytaj oryginał (ang.) |
| Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains? |
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. |
zacks.com |
2024-04-12 13:26:03 |
Czytaj oryginał (ang.) |
| 3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 |
Biotech stocks can offer some of the most explosive, exciting opportunities on the market. That is, if you find the right one. |
investorplace.com |
2024-04-11 16:24:46 |
Czytaj oryginał (ang.) |